TY - JOUR
T1 - A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy
AU - Bae, So Hyun
AU - Heo, Jang Won
AU - Kim, Cinoo
AU - Kim, Tae Wan
AU - Lee, Joo Yong
AU - Song, Su Jeong
AU - Park, Tae Kwann
AU - Moon, Sang Woong
AU - Chung, Hum
PY - 2011/11
Y1 - 2011/11
N2 - Purpose: To report 6-month outcomes of a prospective, randomized study comparing the efficacy and safety between low-fluence photodynamic therapy (PDT) and intravitreal injections of ranibizumab in the treatment of chronic central serous chorioretinopathy. Design: Prospective, randomized, single-center pilot study. Methods: Sixteen eyes with chronic central serous chorioretinopathy were randomized to receive either low-fluence PDT or intravitreal injections of ranibizumab: 8 eyes in the low-fluence PDT group and 8 in the ranibizumab group. Rescue treatment was considered if subretinal fluid was sustained after completion of primary treatment: low-fluence PDT for the ranibizumab group and ranibizumab injection for the low-fluence PDT group. Main outcome measures were excess foveal thickness, resolution of subretinal fluid, choroidal perfusion on indocyanine green angiography, and best-corrected visual acuity. Results: At 3 months, the mean excess foveal thickness was reduced from 74.1 ± 56.0 μm to -35.4 ± 44.5 μm in the low-fluence PDT group (P =.017) and from 26.3 ± 50.6 μm to -23.1 ± 56.5 μm in the ranibizumab group (P =.058). After a single session of PDT, 6 eyes (75%) in the low-fluence PDT group achieved complete resolution of subretinal fluid and reduction of choroidal hyperpermeability, whereas 2 (25%) eyes in the ranibizumab group achieved this after consecutive ranibizumab injections. Four eyes (50%) in the ranibizumab group underwent additional low-fluence PDT and accomplished complete resolution. At 3 months, significant improvement of best-corrected visual acuity was not demonstrated in the low-fluence PDT group (P =.075), whereas it was observed in the ranibizumab group (P =.012). However, the tendency toward improvement of best-corrected visual acuity was not maintained. Conclusions: In terms of anatomic outcomes, the effect of ranibizumab injections was not promising compared with that of low-fluence PDT.
AB - Purpose: To report 6-month outcomes of a prospective, randomized study comparing the efficacy and safety between low-fluence photodynamic therapy (PDT) and intravitreal injections of ranibizumab in the treatment of chronic central serous chorioretinopathy. Design: Prospective, randomized, single-center pilot study. Methods: Sixteen eyes with chronic central serous chorioretinopathy were randomized to receive either low-fluence PDT or intravitreal injections of ranibizumab: 8 eyes in the low-fluence PDT group and 8 in the ranibizumab group. Rescue treatment was considered if subretinal fluid was sustained after completion of primary treatment: low-fluence PDT for the ranibizumab group and ranibizumab injection for the low-fluence PDT group. Main outcome measures were excess foveal thickness, resolution of subretinal fluid, choroidal perfusion on indocyanine green angiography, and best-corrected visual acuity. Results: At 3 months, the mean excess foveal thickness was reduced from 74.1 ± 56.0 μm to -35.4 ± 44.5 μm in the low-fluence PDT group (P =.017) and from 26.3 ± 50.6 μm to -23.1 ± 56.5 μm in the ranibizumab group (P =.058). After a single session of PDT, 6 eyes (75%) in the low-fluence PDT group achieved complete resolution of subretinal fluid and reduction of choroidal hyperpermeability, whereas 2 (25%) eyes in the ranibizumab group achieved this after consecutive ranibizumab injections. Four eyes (50%) in the ranibizumab group underwent additional low-fluence PDT and accomplished complete resolution. At 3 months, significant improvement of best-corrected visual acuity was not demonstrated in the low-fluence PDT group (P =.075), whereas it was observed in the ranibizumab group (P =.012). However, the tendency toward improvement of best-corrected visual acuity was not maintained. Conclusions: In terms of anatomic outcomes, the effect of ranibizumab injections was not promising compared with that of low-fluence PDT.
UR - https://www.scopus.com/pages/publications/80054999144
U2 - 10.1016/j.ajo.2011.04.008
DO - 10.1016/j.ajo.2011.04.008
M3 - Article
AN - SCOPUS:80054999144
SN - 0002-9394
VL - 152
SP - 784-792.e2
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 5
ER -